BioCorRx (BICX) Stock Analysis & Winston Score

Winston Score History

BioCorRx Inc. is a small healthcare company focused on treating addiction, mainly alcohol and opioid dependence. Its core product is the BICX treatment program, which combines a naltrexone implant — a small device placed under the skin that blocks the effects of opioids and alcohol — with counseling support. The company sells its treatment through licensed healthcare providers and addiction treatment clinics across the United States.

BioCorRx earns revenue by licensing its treatment protocol to providers and through product sales related to its implant technology. It is a very small company with a market cap near zero, meaning it has limited financial resources compared to larger pharmaceutical or addiction treatment firms. The high gross margin suggests the core product carries decent pricing power, but the deeply negative operating margin shows the company is spending far more than it earns, which is the central risk — it must raise additional capital or significantly grow revenue to remain a going concern.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-50.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+54.5% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

29.0%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~0 months

$21,237 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

BioCorRx has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-88.2%

Thin — -88.2% gross margin

Profit after running costs

Operating Margin

-1666.0%

Losing money on operations — -1666.0%

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+151.2%

Fast-growing sales (+151.2% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-299.4%

Burning cash (-299.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial